Anji Pharmaceuticals, Inc.

Some three years after COVID-19 kickstarted a massive adoption of digital technology and shift to remote monitoring in clinical development, technology continues to effect seismic changes in the trial

With the US Inflation Reduction Act threatening a major shake-up in drug pricing from 2023 onwards, and with the progress of increasing numbers of costly advanced therapeutics onto the market, one thi

The first half of 2022 saw the NASDAQ Biotechnology Index lose a quarter of its value. Despite a tentative recovery since then, the IPO window is barely ajar and valuations remain well below the highs

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in